Today we issued an updated, 44-page Executive Informational Overview® (EIO®) on BELLUS Health Inc. (BLU-TSX). BELLUS, up more than 100% this morning after announcing the start of a Phase III trial for KIACTA yesterday, is a global health company focused on the research and development of innovative health solutions for critical, unmet medical needs. The Company’s pharmaceutical pipeline targets disorders for which there are no known cures.
BELLUS Health’s most advanced pharmaceutical candidate is KIACTA (eprodisate) to treat Amyloid A (AA) amyloidosis, a disease marked by an abnormal accumulation of certain proteins that can cause organ dysfunction, organ failure, and even death. In December 2010, KIACTA entered a confirmatory Phase III trial funded by Celtic Therapeutics, a global private equity firm, under an April 2010 agreement between BELLUS Health and Celtic.
The Company’s pharmaceutical pipeline also includes NRM8499, a prodrug for Alzheimer’s disease (AD) that entered a Phase I trial in March 2010. Additionally, through a wholly owned subsidiary, OVOS Natural Health Inc., the Company markets a clinically tested nutraceutical called VIVIMIND (tramiprosate/homotaurine) to protect memory function. VIVIMIND is available online and has been granted approval for sale in Canada, Italy, and Spain.
Be the first to hear about Crystal Research’s new report releases and upcoming media coverage. Follow us on Twitter to stay up-to-date on happenings at Crystal Research.